Other studies have also shown that the combination of SIRT1 and SIRT2 is a better predictive model of recurrence-free survival (RFS) in non-small cell lung cancer (NSCLC) to stratify patients (58). This evidence concerns the gene SIRT2 and non-small cell lung carcinoma.